Heron Therapeutics Reports Q2 2026 Financial Results with Mixed Performance

Heron Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net product sales figure of $37.7 million, a slight increase from $37.2 million in the same period last year. However, the company experienced a net loss of $5.5 million, or $0.03 per share, compared to a loss of $2.4 million, or $0.02 per share, in the prior year. For the first half of 2026, net product sales totaled $72.4 million, down from $76.1 million in the first half of 2025, with a net loss of $13.6 million compared to a net income of $0.3 million in the same period last year.

The company's financial performance reflects a mixed picture, with acute care product sales increasing significantly by 43.9% year-over-year in the second quarter, driven by higher unit sales and market share for ZYNRELEF and APONVIE. In contrast, oncology product sales decreased by 15.9% in the same period, attributed to competitive pressures affecting unit sales. The overall gross profit margin for the second quarter was 69.3%, down from 73.5% in the previous year, primarily due to increased costs associated with product sales.

Heron Therapeutics has made strategic moves to enhance its market position, including the expansion of its product offerings and the recent approval of new reimbursement codes for its products. The company has also entered into a Fourth Amendment to its Working Capital Facility Agreement, which waives certain financial covenants and requires a prepayment of $17.5 million. This amendment is intended to provide the company with additional flexibility as it navigates its financial obligations.

Operationally, Heron Therapeutics reported a total employee headcount increase, which contributed to a rise in sales and marketing expenses by 22.3% in the second quarter. The company continues to focus on expanding its customer base and enhancing product adoption rates, particularly for ZYNRELEF and APONVIE, which are critical to its growth strategy. As of June 30, 2026, the company had cash, cash equivalents, and short-term investments totaling $42.7 million, which management believes will be sufficient to meet its anticipated cash requirements for at least the next year.

Looking ahead, Heron Therapeutics remains focused on its commercialization strategy and the potential for future product approvals. The company acknowledges the challenges posed by market conditions and competitive pressures but is optimistic about its ability to leverage its product portfolio and strategic partnerships to drive growth. The management's outlook emphasizes the importance of maintaining liquidity and operational flexibility as it continues to navigate the evolving healthcare landscape.